Novo Nordisk's economic moat is eroding due to increased competition and US drug price pressures, but growth in international ...

New recommendations suggest holding back on SGLT2 inhibitors and GLP-1s among those at a lower risk for cardiovascular or ...

A week on from increases in the cost of Eli Lilly’s weight loss drug Mounjaro (tirzepatide), weight loss medication provider ...